Immunopotentiation of live brucellosis vaccine by adjuvants

Vaccine

Volumn 28, Issue SUPPL. 5, 2010, Pages

  Denisov, Alexander A ^a   Korobovtseva, Yulia S ^a   Karpova, Olga M ^a   Tretyakova, Alla V ^a   Mikhina, Larisa V ^a   Ivanov, Arkadyi V ^b   Salmakov, Konstantin M ^b   Borovick, Roman V ^a  

^a FEDERAL BIOMEDICAL AGENCY OF RUSSIA   (Russian Federation)

^b Federal State Institution Federal Centre of Toxicological and   (Russian Federation)

Author keywords

Adjuvant; Brucella abortus; Brucellosis; Immune response; Live vaccines

Indexed keywords

BRUCELLA VACCINE; IMMUNOLOGICAL ADJUVANT; LARIFAN; LIVE VACCINE; LYMPHOTOXIN; NATRIUM THIOSULPHATE; POLYOXIDONIUM; RIBI ADJUVANT; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; BRUCELLA ABORTUS; BRUCELLOSIS; CELLULAR IMMUNITY; CONTROLLED STUDY; EXPERIMENTAL GUINEA PIG; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOPOTENTIATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MALE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SEROLOGY; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; BRUCELLA ABORTUS; BRUCELLA VACCINE; BRUCELLOSIS; CELL PROLIFERATION; CELL WALL SKELETON; CORD FACTORS; GUINEA PIGS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; LIPID A; LYMPHOTOXIN-ALPHA; MACROPHAGES, PERITONEAL; MALE; ORGANIC CHEMICALS; PHAGOCYTOSIS; PIPERAZINES; POLYMERS;

EID: 77956776064     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.03.054     Document Type: Article

References (31)

1. Titball R.W. Vaccines against intracellular bacterial pathogens. Drug Discov Today 2008, 13:596-600.
2. Corbel M.J. Brucellosis: an overview. Emerg Infect Dis 1997, 3:213-221.
3. Yingst S., Hoover D.L. T cell immunity to brucellosis. Crit Rev Microbiol 2003, 29:313-331.
4. Seder R.A., Hill A.V. Vaccines against intracellular infections requiring cellular immunity. Nature 2000, 406:793-798.
5. Bonneville M., Scotet E. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol 2006, 18:539-546.
6. Jacques I., Cloeckaert A., Limet J.N., Dubray G. Protection conferred on mice by combinations of monoclonal antibodies directed against outer-membrane proteins or smooth lipopolysaccharide of Brucella. J Med Microbiol 1992, 37:100-113.
7. Bowden R.A., Cloeckaert A., Zygmunt M., Dubray G. Outer membrane protein and rough lipopolysaccharide-specific monoclonal antibodies protect mice against Brucella ovis. J Med Microbiol 1995, 43:344-347.
8. Buck J.M. Studies of vaccination during calfhood to prevent bovine infectious abortion. J Agric Res 1930, 41:667.
9. De Vries R.R.P., Rood J.J.van. HLA and infectious diseases: Ir genes and natural selection-tissue antigens 1977, 10(3):212.
10. Davis D.S., Templeton J.W., Ficht T.A., Huber J.D., Angus R.D., Adams LGl. Brucella abortus in bison II. Evaluation of strain 19 vaccination of pregnant cows. J Wildl Dis 1991, 27(2):258-264.
11. Thorne E.T., Walthall T.J., Dawson H.A. Efficacy of vaccination of elk with strain 19 Brucella abortus. Proc. 85th Ann. Mtg. US Animal Health Assoc 1981, 359-374.
12. Palmer M.V., Olsen S.C., Gilsdorf M.J., Philo L.M., Clarke P.R., Cheville N.F. Abortion and placentitis in pregnant bison (Bison bison) induced by the vaccine candidate, Brucella abortus strain RB51. Am J Vet Res 1996, 57:1604-1607.
13. Kreeger T.J., Miller M.W., Wild M.A., Elzer P.H., Olsen S.C. Safety and efficacy of Brucella abortus strain RB51 vaccine in captive pregnant elk. J Wildl Dis 2000, 36:477-483.
14. Kwissa M., Kasturi S.P., Pulendran B. The science of adjuvants. Expert Rev Vaccines 2007, 6:673-684.
15. Hauguel T.M., Hackett C.J. Rationally designed vaccine adjuvants: separating efficacy from toxicity. Front Biosci 2008, 13:2806-2813.
16. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009, 1:23-32.
17. Wack A., Rappuoli R. Vaccinology at the beginning of the 21st century. Curr Opin Immunol 2005, 17:411-418.
18. Hearth A.W., Playfair J.H.L. Cytokines as immunological adjuvants. Vaccine 1992, 10:427-434.
19. Gaertner F.H., Babiuk L.A., Mutwiri GArmstrong J.M., Griebel P.J. Amended recombinant cells (ARCs™) expressing bovine IFN-γ: an economical and highly effective adjuvant system. Vaccine 2009, 27(9):1377-1385.
20. Su B., Wang J., Wang X., Jin H., Zhao G., Ding Z., et al. The effects of IL-6 and TNF-α as molecular adjuvants on immune responses to FMDV and maturation of dendritic cells by DNA vaccination. Vaccine 2008, 26(40):5111-5122.
21. al-Ramadi B.K., Adeghate E., Mustafa N., Ponery A.S., Fernandez-Cabezudo M.J. Cytokine expression by attenuated intracellular bacteria regulates the immune response to infection: the Salmonella model. Mol Immunol 2002, 38:931-940.
22. Salmakov K.M., Belozerova G.A. Testing of vaccine strain 82-PS on large horned cattle. Abstracts of All-Union Conference "Urgent Questions of Epizootology" 1983, 66-67.
23. Salmakov KM, Belozerova GA. SU Patent (Soviet Union) #1,824,737, March 05; 1994. Live vaccine for prophylaxis of cattle brucellosis from B. abortus 82-PS strain.
24. Shuralev E.A., Salmakov K.M. Study of vaccine immunogenicity of vaccine strain B. abortus 82-PS on guinea pigs at combined application with immunomodulators. Diagnostics, treatment and prophylaxis of infectious diseases. Biotechnology. Veterinary 1999, 297-298.
25. Petrov R.V., Khaitov R.M., Nekrasov A.V., Attaukllakhanov R.I., Puchkova N.G., Ivanova A.C., et al. Polyoxydonium-immunomodulator of the newest generation: results of 3-year clinical application. Allergy Asthma Clin Immunol 1999, 3:3-6.
26. Shuralev E.A., Salmakov K.M. Effectiveness of application of immunomodulators at brucellosis vaccinoprophylaxis. Diagnostics, treatment and prophylaxis of infectious diseases. Biotechnology. Veterinary 1999, 66-67.
27. Knoroz MIu, Popova O.M., Davydova A.A., Nosik I.N., Barinskiǐ I.F. Comparative study of the antiviral activity of natural double-stranded RNAs in experimental tick-borne encephalitis. Vopr Virusol 1985, 30(6):697-700.
28. Rudbach J.A., Johnson D.A., Ulrich J.T. Ribi adjuvants: chemistry, biology and utility in vaccines for human and veterinary medicine. The theory and practical application of adjuvants 1995, 287-313. Wiley, Chichester. D.E.S. Stewart-Tull (Ed.).
29. Denisov A.A., Torskyi S.P., Nikolaeva O.G., Volojantseva I.Y. Recombinant human lymphotoxin: synthesis in Escherichia coli, purification and some properties. Biochemistry (Mosc) 1995, 60(9):1403-1410.
30. Denisov A.A., Pinegin B.V., Kulakov V.V., Mikhina L.V., Nikolaeva O.G., Martinov A.I. Immunoregulating activity of recombinant human lymphotoxin. Immunology (Mosc) 1996, 4:34-39.
31. United States Animal Health Association Enhancing Brucellosis Vaccines, Vaccine Delivery and Surveillance Diagnostics for Elk and Bison in the Greater Yellowstone Area: A Technical Report from a Working Symposium 2006, The University of Wyoming Haub School and Ruckelshaus Institute of Environment and Natural Resources, WY 82071, 80 pp. Terry Kreeger, Glenn Plumb (Eds.).